FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Frontage Holdings Corporation Stock AnalysisComprehensive stock analysis for Frontage Holdings Corporation (FGHQF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisFGHQF
FGHQF
Frontage Holdings Corporation
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
FGHQF
Home🔹Stocks🔹Frontage Holdings Corporation

Frontage Holdings Corporation

🇺🇸FGHQF•OTC

Frontage Holdings Corporation

🇺🇸FGHQF•OTC
Market cap
$283.88M
Sentiment

Your view on FGHQF

Mkt Cap
$283.88M
Sentiment
Your view
FGHQF
Frontage Holdings Corporation
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
FGHQF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Frontage Holdings Corporation

Industry
Biotechnology
Sector
Healthcare
CEO
Zhongping Lin
Headquarters
700 Pennsylvania Drive, Exton, PA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Zhongping Lin
Headquarters
700 Pennsylvania Drive, Exton, PA, US
Description

Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies, as well as bioequivalence studies.

It offers laboratory testing services, such as method development and validation, and sample analysis and central laboratory services; chemistry, manufacturing, and control services, including assistance in drug product development and analysis, and delivery and supply of clinical trial materials; and drug metabolism and pharmacokinetic services that include study designs, execution of studies, and interpretation of the data through structural optimization in early discovery, pharmacokinetic studies in rodents, non- GLP bioanalytical studies, etc. The company also provides safety and toxicology services comprising in-vitro and in-vivo studies; bioequivalence services, which consist of designing, coordinating, and reporting of bioequivalence studies; chemistry services comprising contract research and custom synthesis services; and clinical services, such as early stage clinical, BE/BA, biometric, and data management services.

It operates in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. The company was incorporated in 2018 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Frontage Holdings Corporation, and the rating behind it. FGHQF last traded at $0.14, 29.4× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Frontage Holdings Corporation. Starting points for Frontage Holdings Corporation: P/E 29.4, EPS $0.0052, beta 0.30 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Frontage Holdings Corporation. Frontage Holdings Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Frontage Holdings Corporation. Trailing twelve-month EPS for Frontage Holdings Corporation stands at $0.0052. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Frontage Holdings Corporation. Frontage Holdings Corporation has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Frontage Holdings Corporation valued side by side against its closest peers. Frontage Holdings Corporation is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Frontage Holdings Corporation, and how their positions are changing. At a $283.9M market value, institutional positions materially move Frontage Holdings Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Frontage Holdings Corporation executives and directors. Shares of Frontage Holdings Corporation have traded between $0.10 and $0.15 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Frontage Holdings Corporation. Frontage Holdings Corporation is a $283.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Frontage Holdings Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Frontage Holdings Corporation. Coverage tracks Frontage Holdings Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • CLVLF — Clinuvel Pharmaceuticals Limited
  • CYDY — CytoDyn Inc.
  • HNSBF — Hansa Biopharma AB (publ)
  • IDGXF — Integrated Diagnostics Holdings plc
  • OPORF — hVIVO plc

More Biotechnology companies

  • NTRBW — Nutriband Inc.
  • NTRR — Neutra Corp.
  • NURPF — Neuren Pharmaceuticals Limited
  • NUVB — Nuvation Bio Inc.
  • NUZ.AX — Neurizon Therapeutics Limited
  • NVAX — Novavax, Inc.
  • NVCT — Nuvectis Pharma, Inc.
  • NWBO — Northwest Biotherapeutics, Inc.
  • NWPHF — Newron Pharmaceuticals S.p.A.
  • NXTC — NextCure, Inc.
  • NYMXF — Nymox Pharmaceutical Corporation
  • NYR.AX — Nyrada Inc.

News

Latest Market News